European Journal of Clinical Pharmacology

, Volume 68, Issue 5, pp 747–755

Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies

  • Chun Shing Kwok
  • Jessica Ka-Yan Yeong
  • Richard M. Turner
  • Rodrigo Cavallazzi
  • Sonal Singh
  • Yoon Kong Loke
Pharmacoepidemiology and Prescription

Abstract

Purpose

Statins have potential anti-inflammatory effects, but the association between statin use and lower incidence of pneumonia is unclear. We have therefore performed a systematic review on the risk of pneumonia in statin users versus non-users.

Methods

MEDLINE and EMBASE were searched in December 2010 for controlled observational studies that reported on the risk of pneumonia in statin users. We performed a random effects meta-analysis and assessed heterogeneity using the I2 statistic.

Results

A total of 451 citations were screened, and ultimately nine studies (4 case–control, 4 retrospective cohort, 1 prospective cohort) with more than 3 million participants were included in the meta-analysis. Pooled analysis of seven studies that reported unadjusted data failed to show a significantly reduced risk of pneumonia [odds ratio (OR) 0.94, 95% confidence interval (CI) 0.84–1.06, p = 0.33, I2 = 79%] in statin users as compared to non-users. However, a significant reduction in the likelihood of pneumonia associated with statin use (n = 8 studies, OR 0.85, 95% CI 0.75–0.97, p = 0.02, I2 = 81%) was found in the meta-analysis of adjusted data. Both analyses were limited by substantial statistical heterogeneity. Sensitivity analysis failed to fully clarify the source of heterogeneity, but cohort studies seemed to be less heterogenous (n = 5 studies, OR 0.92, 95% CI 0.84–1.01, I2 = 43%).

Conclusion

Our findings indicate that the purported benefit of statins in preventing pneumonia is inconsistent, and of low magnitude, with upper bounds of the confidence interval being close to null. In view of the substantial statistical and clinical heterogeneity in the dataset, there is no convincing evidence to support the therapeutic application of statins for reducing the risk of pneumonia.

Keywords

Statins Pneumonia Meta-analysis 

References

  1. 1.
    Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT (2010) Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med 104(8):1081–1091PubMedCrossRefGoogle Scholar
  2. 2.
    Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:977–987PubMedCrossRefGoogle Scholar
  3. 3.
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278PubMedCrossRefGoogle Scholar
  4. 4.
    Fedson DS (2006) Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 43:199–205PubMedCrossRefGoogle Scholar
  5. 5.
    Alegret M, Silvestre JS (2006) Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol 28:627–656PubMedCrossRefGoogle Scholar
  6. 6.
    Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63:12–23PubMedCrossRefGoogle Scholar
  7. 7.
    Novack V, Terblanche M, Almog Y (2006) Do statins have a role in preventing or treating sepsis? Crit Care 10:113PubMedCrossRefGoogle Scholar
  8. 8.
    Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as anti-inflammatory agents? Circulation 109[21 suppl 1]:II18–II26PubMedGoogle Scholar
  9. 9.
    Almog Y (2003) Statins, inflammation, and sepsis: hypothesis. Chest 124:740–743PubMedCrossRefGoogle Scholar
  10. 10.
    Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H (2007) The effect of statin therapy on infection related mortality in patients with atherosclerotic diseases. Crit Care Med 35:372–378PubMedCrossRefGoogle Scholar
  11. 11.
    Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880–885PubMedCrossRefGoogle Scholar
  12. 12.
    Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352–1357PubMedCrossRefGoogle Scholar
  13. 13.
    Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR (2007) Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 27(3):325–332PubMedCrossRefGoogle Scholar
  14. 14.
    van den Garde EMW, Hak E, Souvereins PC, Hoes AW, van den Bosch JMM, Leufkens HGM (2006) Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 61:957–961PubMedCrossRefGoogle Scholar
  15. 15.
    Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA (2009) Statin use and risk of community acquired pneumonia in older people: population based case-control study. Br Med J 338:b2137. doi:10.1136/bmj.b2137 CrossRefGoogle Scholar
  16. 16.
    Fleming DM, Verlander NQ, Elliot AJ, Zhao H, Gelb D, Jehring D, Nguyen-van-tam JS (2010) An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998–1999 to 2005–2006. Epidemiol Infect 138:1281–1288PubMedCrossRefGoogle Scholar
  17. 17.
    Kwong JC, Li P, Redelmeier DA (2009) Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS ONE 4(11):8087CrossRefGoogle Scholar
  18. 18.
    Douglas I, Evans S, Smeeth L (2011) Effect of statin treatment on short term mortality after pneumonia episode: cohort study. Br Med J 342:d1642CrossRefGoogle Scholar
  19. 19.
    Yende S, Milbrandt EB, Kellum JA, Kong L, Delude RL, Weissfeld LA, Angus DC (2011) Understanding the role of statins in pneumonia and sepsis. Crit Care Med 39(8):1871–1878Google Scholar
  20. 20.
    Singh S, Loke YK, Furberg CD (2011) Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. Thorax 66(5):383–388PubMedCrossRefGoogle Scholar
  21. 21.
    Loke YK, Price D, Herxheimer A (2008) Chapter 14: adverse effects. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, ChichesterGoogle Scholar
  22. 22.
    Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. Can Med Assoc J 176(8):1091–1096Google Scholar
  23. 23.
    Davies HT, Crombie IK, Tavakoli M (1998) When can odds ratios mislead? Br Med J 316(7136):989–991CrossRefGoogle Scholar
  24. 24.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327(7414):557–560CrossRefGoogle Scholar
  25. 25.
    Le Manach Y, Ibanez Esteves C, Bertrand M, Goarin JP, Fleron MH, Coriat P, Koskas F, Fiou B, Landais P (2011) Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing vascular surgery. Anesthesiology 114(1):98–104PubMedCrossRefGoogle Scholar
  26. 26.
    Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE (2009) Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 18(4):269–275PubMedCrossRefGoogle Scholar
  27. 27.
    Rodriguez de Antonio LA, Martinez-Sanchez P, Martinez-Martinez MM, Cazorla-Garcia R, Sanz-Gallego FB, Diez-Tejedor E (2011) Previous statins treatment and risk of post-stroke infections. Neurologia 26:150–156PubMedCrossRefGoogle Scholar
  28. 28.
    Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67(1):99–109PubMedCrossRefGoogle Scholar
  29. 29.
    Ioannidis JP, Patsopoulos NA, Rothstein HR (2008) Reasons or excuses for avoiding meta-analysis in forest plots. Br Med J 336:1413–1415CrossRefGoogle Scholar
  30. 30.
    Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. Br Med J 333(7576):999CrossRefGoogle Scholar
  31. 31.
    Schisterman EF, Cole SR, Platt RW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20(4):488–495PubMedCrossRefGoogle Scholar
  32. 32.
    Fessler MB, Young SK, Jeyaseelan S, Lieber JG, Arndt PG, Nick JA, Worthern GS (2005) A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Med 171(6):606–615CrossRefGoogle Scholar
  33. 33.
    Whittle J, Fine MJ, Joyce DZ, Lave JR, Young WW, Hough LJ, Kapoor WN (1997) Community-acquired pneumonia: can it be defined with claims data? Am J Med Qual 12(4):187–193PubMedCrossRefGoogle Scholar
  34. 34.
    Beri A, Surai N, Mahajan SB (2009) Non-atheroprotective effects of statins: a systematic review. Am J Cardiovasc Drugs 9(6):361–370PubMedCrossRefGoogle Scholar
  35. 35.
    Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Br Med J 340:c2197. doi:10.1136/bmj.c2197
  36. 36.
    Marston BJ, Plouffe JF, File TM Jr, Hackman BA, Salstrom SJ, Lipman HB, Kolczak MS, Breiman RF (1997) Incidence of community-acquired pneumonia requiring hospitalization Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157(15):1709–1718PubMedCrossRefGoogle Scholar
  37. 37.
    Loke YK, Kwok CS, Niruban A, Myint PK (2010) Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax 65(10):884–890PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Chun Shing Kwok
    • 1
  • Jessica Ka-Yan Yeong
    • 1
  • Richard M. Turner
    • 2
  • Rodrigo Cavallazzi
    • 3
  • Sonal Singh
    • 4
  • Yoon Kong Loke
    • 1
  1. 1.School of MedicineUniversity of East AngliaNorwichUK
  2. 2.Norfolk and Norwich University HospitalColney LaneNorwichUK
  3. 3.Department of MedicineUniversity of LouisvilleLouisvilleUSA
  4. 4.Department of MedicineJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations